This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-28-5p | AAGAB | -0.14 | 0.04976 | 0.81 | 0 | miRanda | -0.26 | 0 | NA | |
2 | hsa-miR-28-5p | AATK | -0.14 | 0.04976 | 0.45 | 0.00408 | miRanda | -0.27 | 0.00027 | NA | |
3 | hsa-miR-107 | ABCA6 | 0.68 | 0 | -3.37 | 0 | miRanda | -0.73 | 0 | NA | |
4 | hsa-miR-338-3p | ABCA6 | 0.08 | 0.57514 | -3.37 | 0 | miRanda | -0.26 | 0 | NA | |
5 | hsa-miR-342-3p | ABCA6 | 1.22 | 0 | -3.37 | 0 | miRanda | -0.3 | 0 | NA | |
6 | hsa-miR-590-3p | ABCA6 | 1.27 | 0 | -3.37 | 0 | miRanda | -0.59 | 0 | NA | |
7 | hsa-miR-590-5p | ABCA6 | 0.75 | 0 | -3.37 | 0 | miRanda | -0.57 | 0 | NA | |
8 | hsa-miR-320b | ABCA8 | 0.41 | 0.00113 | -5.12 | 0 | miRanda | -0.61 | 0 | NA | |
9 | hsa-miR-375 | ABCA8 | 2.1 | 0 | -5.12 | 0 | miRanda | -0.2 | 1.0E-5 | NA | |
10 | hsa-miR-590-3p | ABCA8 | 1.27 | 0 | -5.12 | 0 | miRanda | -1.07 | 0 | NA | |
11 | hsa-miR-28-5p | ABCB9 | -0.14 | 0.04976 | 0.95 | 0 | miRanda | -0.26 | 0 | NA | |
12 | hsa-miR-28-5p | ABCC5 | -0.14 | 0.04976 | 0.8 | 0 | miRanda | -0.16 | 0.00553 | NA | |
13 | hsa-miR-28-5p | ABHD1 | -0.14 | 0.04976 | -0.98 | 0 | miRanda | -0.3 | 7.0E-5 | NA | |
14 | hsa-miR-28-5p | ABLIM3 | -0.14 | 0.04976 | -1.88 | 0 | miRanda | -0.64 | 0 | NA | |
15 | hsa-miR-28-5p | ACACA | -0.14 | 0.04976 | -0.22 | 0.02162 | miRanda | -0.16 | 0.00043 | NA | |
16 | hsa-miR-107 | ACACB | 0.68 | 0 | -3.51 | 0 | miRanda | -0.42 | 0 | NA | |
17 | hsa-miR-324-5p | ACACB | 0.21 | 0.13941 | -3.51 | 0 | miRanda | -0.34 | 0 | NA | |
18 | hsa-miR-455-5p | ACACB | 0.28 | 0.03576 | -3.51 | 0 | miRanda | -0.22 | 1.0E-5 | NA | |
19 | hsa-miR-28-5p | ACAD8 | -0.14 | 0.04976 | -0.36 | 0 | miRanda | -0.12 | 0.00017 | NA | |
20 | hsa-miR-375 | ACADL | 2.1 | 0 | -5.19 | 0 | miRanda | -0.36 | 0 | NA | |
21 | hsa-miR-28-5p | ACAT1 | -0.14 | 0.04976 | -0.75 | 0 | miRanda | -0.16 | 0.00027 | NA | |
22 | hsa-miR-28-5p | ACOX3 | -0.14 | 0.04976 | 0.2 | 0.02327 | miRanda | -0.18 | 1.0E-5 | NA | |
23 | hsa-miR-28-5p | ACSF2 | -0.14 | 0.04976 | -0.26 | 0.05489 | miRanda | -0.31 | 0 | NA | |
24 | hsa-miR-375 | ACSL4 | 2.1 | 0 | -1.48 | 0 | miRanda | -0.21 | 0 | NA | |
25 | hsa-miR-107 | ACSM5 | 0.68 | 0 | -3.68 | 0 | miRanda | -0.44 | 0 | NA | |
26 | hsa-miR-320b | ACSM5 | 0.41 | 0.00113 | -3.68 | 0 | miRanda | -0.32 | 0 | NA | |
27 | hsa-miR-590-3p | ACSM5 | 1.27 | 0 | -3.68 | 0 | miRanda | -0.6 | 0 | NA | |
28 | hsa-miR-28-5p | ADAMTS13 | -0.14 | 0.04976 | 0.49 | 0.00058 | miRanda | -0.25 | 0.0002 | NA | |
29 | hsa-miR-375 | ADAMTS3 | 2.1 | 0 | -1.85 | 0 | miRanda | -0.21 | 0 | NA | |
30 | hsa-miR-28-5p | ADCK1 | -0.14 | 0.04976 | 0.19 | 0.00451 | miRanda | -0.12 | 0.00012 | NA | |
31 | hsa-miR-28-5p | ADCY1 | -0.14 | 0.04976 | -0.05 | 0.84149 | miRanda | -0.59 | 0 | NA | |
32 | hsa-miR-375 | ADCY3 | 2.1 | 0 | -0.58 | 0 | miRanda | -0.12 | 0 | NA | |
33 | hsa-miR-28-5p | ADCY6 | -0.14 | 0.04976 | -0.63 | 0 | miRanda | -0.32 | 0 | NA | |
34 | hsa-miR-342-3p | ADH1B | 1.22 | 0 | -7.23 | 0 | miRanda | -0.54 | 2.0E-5 | NA | |
35 | hsa-miR-429 | ADH1B | 2.84 | 0 | -7.23 | 0 | miRanda | -1.08 | 0 | NA | |
36 | hsa-miR-590-3p | ADH1B | 1.27 | 0 | -7.23 | 0 | miRanda | -1.26 | 0 | NA | |
37 | hsa-miR-590-3p | ADH1C | 1.27 | 0 | -5.26 | 0 | miRanda | -0.93 | 0 | NA | |
38 | hsa-miR-320b | ADIPOQ | 0.41 | 0.00113 | -7.2 | 0 | miRanda | -0.72 | 0 | NA | |
39 | hsa-miR-330-5p | ADIPOQ | 0.63 | 0 | -7.2 | 0 | miRanda | -1.12 | 0 | NA | |
40 | hsa-miR-339-5p | ADIPOQ | -0.21 | 0.06859 | -7.2 | 0 | miRanda | -0.33 | 0.03308 | NA | |
41 | hsa-miR-429 | ADIPOQ | 2.84 | 0 | -7.2 | 0 | miRanda | -1.06 | 0 | NA | |
42 | hsa-miR-590-3p | ADIPOQ | 1.27 | 0 | -7.2 | 0 | miRanda | -1.2 | 0 | NA | |
43 | hsa-miR-28-5p | AFF1 | -0.14 | 0.04976 | -0.82 | 0 | miRanda | -0.18 | 2.0E-5 | NA | |
44 | hsa-miR-28-5p | AFF4 | -0.14 | 0.04976 | -0.28 | 0.00153 | miRanda | -0.2 | 0 | NA | |
45 | hsa-miR-28-5p | AFTPH | -0.14 | 0.04976 | 0.31 | 0 | miRanda | -0.1 | 0.00074 | NA | |
46 | hsa-miR-28-5p | AGAP11 | -0.14 | 0.04976 | -2.72 | 0 | miRanda | -0.31 | 0.00022 | NA | |
47 | hsa-miR-28-5p | AGBL4 | -0.14 | 0.04976 | -0.14 | 0.45129 | miRanda | -0.24 | 0.00912 | NA | |
48 | hsa-miR-155-5p | AGTR1 | 1.1 | 0 | -2.44 | 0 | miRTarBase | -0.57 | 0 | 22525818 | MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer |
49 | hsa-miR-28-5p | AHNAK | -0.14 | 0.04976 | -1.77 | 0 | miRanda | -0.27 | 0 | NA | |
50 | hsa-miR-183-5p | AKAP12 | 2.96 | 0 | -2.76 | 0 | miRTarBase | -0.54 | 0 | NA | |
51 | hsa-miR-375 | AKAP6 | 2.1 | 0 | -2.28 | 0 | miRanda | -0.11 | 0 | NA | |
52 | hsa-miR-375 | AKAP7 | 2.1 | 0 | -1.02 | 0 | miRanda | -0.11 | 0 | NA | |
53 | hsa-miR-28-5p | AKR7A2 | -0.14 | 0.04976 | 0.34 | 1.0E-5 | miRanda | -0.24 | 0 | NA | |
54 | hsa-miR-15a-5p | AKT3 | 0.81 | 0 | -1.39 | 0 | miRTarBase | -0.51 | 0 | NA | |
55 | hsa-miR-107 | ALB | 0.68 | 0 | -3.87 | 0 | miRanda | -0.72 | 0 | NA | |
56 | hsa-miR-193a-3p | ALB | 0.31 | 0.00478 | -3.87 | 0 | miRanda | -0.39 | 0.00094 | NA | |
57 | hsa-miR-320b | ALB | 0.41 | 0.00113 | -3.87 | 0 | miRanda | -0.46 | 1.0E-5 | NA | |
58 | hsa-miR-339-5p | ALB | -0.21 | 0.06859 | -3.87 | 0 | miRanda | -0.27 | 0.01599 | NA | |
59 | hsa-miR-590-3p | ALB | 1.27 | 0 | -3.87 | 0 | miRanda | -0.74 | 0 | NA | |
60 | hsa-miR-107 | ALDH1A2 | 0.68 | 0 | -3.85 | 0 | miRanda | -0.75 | 0 | NA | |
61 | hsa-miR-142-3p | ALDH1A2 | 1.54 | 0 | -3.85 | 0 | miRanda | -0.24 | 0 | NA | |
62 | hsa-miR-330-5p | ALDH1A2 | 0.63 | 0 | -3.85 | 0 | miRanda | -0.68 | 0 | NA | |
63 | hsa-miR-338-3p | ALDH1A2 | 0.08 | 0.57514 | -3.85 | 0 | miRanda | -0.23 | 0.0001 | NA | |
64 | hsa-miR-28-5p | ALDH3A2 | -0.14 | 0.04976 | -0.86 | 0 | miRanda | -0.29 | 0 | NA | |
65 | hsa-miR-146b-5p | AMIGO2 | 0.63 | 0 | -1.58 | 0 | miRanda | -0.11 | 0.03887 | NA | |
66 | hsa-miR-28-5p | AMIGO2 | -0.14 | 0.04976 | -1.58 | 0 | miRanda | -0.24 | 0.00784 | NA | |
67 | hsa-miR-330-5p | AMIGO2 | 0.63 | 0 | -1.58 | 0 | miRanda | -0.23 | 0.00016 | NA | |
68 | hsa-miR-361-5p | AMIGO2 | -0.1 | 0.09543 | -1.58 | 0 | miRanda | -0.3 | 0.00637 | NA | |
69 | hsa-miR-28-5p | AMPH | -0.14 | 0.04976 | -0.23 | 0.25767 | miRanda | -0.38 | 8.0E-5 | NA | |
70 | hsa-miR-28-5p | AMZ1 | -0.14 | 0.04976 | 2.49 | 0 | miRanda | -0.45 | 0.00014 | NA | |
71 | hsa-miR-28-5p | ANGEL1 | -0.14 | 0.04976 | -0.24 | 5.0E-5 | miRanda | -0.14 | 0 | NA | |
72 | hsa-miR-21-5p | ANKRD46 | 2.32 | 0 | -0.46 | 0 | miRTarBase | -0.31 | 0 | 21219636 | Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein levels; ANKRD46 is newly identified as a direct target of miR-21 in BC |
73 | hsa-miR-28-5p | ANKS1B | -0.14 | 0.04976 | 0.2 | 0.2194 | miRanda | -0.42 | 0 | NA | |
74 | hsa-miR-28-5p | ANKS3 | -0.14 | 0.04976 | 0.72 | 0 | miRanda | -0.16 | 0.0011 | NA | |
75 | hsa-miR-375 | ANO4 | 2.1 | 0 | -1.89 | 0 | miRanda | -0.13 | 0 | NA | |
76 | hsa-miR-28-5p | ANXA9 | -0.14 | 0.04976 | 1.78 | 0 | miRanda | -1.05 | 0 | NA | |
77 | hsa-miR-28-5p | AP2A2 | -0.14 | 0.04976 | 0.03 | 0.55943 | miRanda | -0.12 | 0 | NA | |
78 | hsa-miR-28-5p | AP2B1 | -0.14 | 0.04976 | 0.26 | 0.00183 | miRanda | -0.22 | 0 | NA | |
79 | hsa-miR-375 | APBB1IP | 2.1 | 0 | -1.19 | 0 | miRanda | -0.13 | 0 | NA | |
80 | hsa-miR-155-5p | APC | 1.1 | 0 | -0.69 | 0 | miRTarBase | -0.15 | 0 | 23796566 | Upregulated miR 155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β catenin signaling; We have searched for miR-155 targets and identified the hypothesis that miR-155 could promote tumor growth of PTC by targeted regulation of adenomatous polyposis coli APC expression and activating the Wnt/β-catenin signaling; Further studies revealed that APC is a novel miR-155 target because miR-155 bound directly to its 3'-untranslated region and reduced both the mRNA and protein levels of APC; Similar to the miR-155 over-expression APC downregulation promoted cell growth whereas rescued APC expression reversed the promotive effect of miR-155; By targeting APC miR-155 efficiently regulates the Wnt/β-catenin signaling |
81 | hsa-miR-375 | APLF | 2.1 | 0 | -0.95 | 0 | miRanda | -0.15 | 0 | NA | |
82 | hsa-miR-375 | APOB | 2.1 | 0 | -5.96 | 0 | miRanda | -0.29 | 0 | NA | |
83 | hsa-miR-142-3p | APOD | 1.54 | 0 | -3.12 | 0 | miRanda | -0.24 | 0 | NA | |
84 | hsa-miR-375 | AQP4 | 2.1 | 0 | -2.95 | 0 | miRanda | -0.17 | 0 | NA | |
85 | hsa-miR-28-5p | ARAF | -0.14 | 0.04976 | 0.24 | 1.0E-5 | miRanda | -0.11 | 4.0E-5 | NA | |
86 | hsa-miR-107 | AREG | 0.68 | 0 | -0.78 | 0.00739 | miRanda | -0.41 | 0.00063 | NA | |
87 | hsa-miR-330-5p | AREG | 0.63 | 0 | -0.78 | 0.00739 | miRanda | -0.34 | 0.00033 | NA | |
88 | hsa-miR-590-3p | AREG | 1.27 | 0 | -0.78 | 0.00739 | miRanda | -0.41 | 0 | NA | |
89 | hsa-miR-28-5p | ARHGAP32 | -0.14 | 0.04976 | 0.43 | 9.0E-5 | miRanda | -0.36 | 0 | NA | |
90 | hsa-miR-28-5p | ARHGAP8 | -0.14 | 0.04976 | 1.29 | 0 | miRanda | -0.12 | 0.04559 | NA | |
91 | hsa-miR-28-5p | ARHGEF16 | -0.14 | 0.04976 | 1.35 | 0 | miRanda | -0.31 | 0 | NA | |
92 | hsa-miR-155-5p | ARID2 | 1.1 | 0 | 0.01 | 0.8705 | miRTarBase | -0.13 | 0 | 27035278 | MicroRNA 155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2 |
93 | hsa-miR-28-5p | ARL17A | -0.14 | 0.04976 | -0.08 | 0.37677 | miRanda | -0.12 | 0.00459 | NA | |
94 | hsa-miR-429 | ARL4A | 2.84 | 0 | -1.62 | 0 | miRanda | -0.18 | 0 | NA | |
95 | hsa-miR-28-5p | ARL6IP4 | -0.14 | 0.04976 | 0.5 | 0 | miRanda | -0.19 | 0.00019 | NA | |
96 | hsa-miR-28-5p | ARMC5 | -0.14 | 0.04976 | 0.67 | 0 | miRanda | -0.28 | 0 | NA | |
97 | hsa-miR-28-5p | ARMC7 | -0.14 | 0.04976 | 0.79 | 0 | miRanda | -0.13 | 0.00026 | NA | |
98 | hsa-miR-28-5p | ARMC9 | -0.14 | 0.04976 | 1.05 | 0 | miRanda | -0.18 | 0 | NA | |
99 | hsa-miR-28-5p | ASB8 | -0.14 | 0.04976 | -0.21 | 0.00012 | miRanda | -0.19 | 0 | NA | |
100 | hsa-miR-28-5p | ATPAF1 | -0.14 | 0.04976 | -0.16 | 0.00532 | miRanda | -0.12 | 1.0E-5 | NA | |
101 | hsa-miR-28-5p | ATRNL1 | -0.14 | 0.04976 | -0.74 | 0.02081 | miRanda | -0.53 | 0.00049 | NA | |
102 | hsa-miR-375 | AVPR1A | 2.1 | 0 | -2.1 | 0 | miRanda | -0.11 | 5.0E-5 | NA | |
103 | hsa-miR-15b-5p | AXIN2 | 0.79 | 0 | -0.9 | 0 | miRTarBase | -0.25 | 0 | NA | |
104 | hsa-miR-28-5p | B3GALT4 | -0.14 | 0.04976 | 0.46 | 1.0E-5 | miRanda | -0.14 | 0.00301 | NA | |
105 | hsa-miR-28-5p | BAG1 | -0.14 | 0.04976 | 0.42 | 2.0E-5 | miRanda | -0.31 | 0 | NA | |
106 | hsa-miR-375 | BAHCC1 | 2.1 | 0 | -0.35 | 0.00682 | miRanda | -0.11 | 0 | NA | |
107 | hsa-miR-107 | BBOX1 | 0.68 | 0 | -3.62 | 0 | miRanda | -0.81 | 0 | NA | |
108 | hsa-miR-342-3p | BBOX1 | 1.22 | 0 | -3.62 | 0 | miRanda | -0.84 | 0 | NA | |
109 | hsa-miR-28-5p | BBS1 | -0.14 | 0.04976 | -0.09 | 0.27359 | miRanda | -0.29 | 0 | NA | |
110 | hsa-miR-28-5p | BCAM | -0.14 | 0.04976 | 0.51 | 0.00081 | miRanda | -0.64 | 0 | NA | |
111 | hsa-miR-375 | BCL11B | 2.1 | 0 | -0.26 | 0.19747 | miRanda | -0.16 | 0 | NA | |
112 | hsa-miR-148a-3p | BCL2 | 0.71 | 0 | -0.9 | 0 | miRTarBase | -0.22 | 0 | 21455217; 23975374 | MiR 148a promotes apoptosis by targeting Bcl 2 in colorectal cancer;MiR 148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl 2; Using western blot and luciferase activity assay CCKBR and Bcl-2 were identified as targets of miR-148a; Moreover we also found that the expression of Bcl-2 lacking in 3'UTR could abrogate the pro-apoptosis function of miR-148a |
113 | hsa-miR-15a-5p | BCL2 | 0.81 | 0 | -0.9 | 0 | miRTarBase | -0.39 | 0 | 25594541; 22335947; 26915294; 18931683; 25623762 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;The expression of MiR-15a was significantly inhibited by Bcl-2 P < 0.05;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells |
114 | hsa-miR-15b-5p | BCL2 | 0.79 | 0 | -0.9 | 0 | miRTarBase | -0.28 | 0 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
115 | hsa-miR-21-5p | BCL2 | 2.32 | 0 | -0.9 | 0 | miRTarBase | -0.49 | 0 | 26555418; 21468550; 25994220; 25381586; 23359184; 22964582; 21376256 | The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
116 | hsa-miR-375 | BCL2L14 | 2.1 | 0 | -0.13 | 0.58205 | miRanda | -0.16 | 0 | NA | |
117 | hsa-miR-155-5p | BCL6 | 1.1 | 0 | -1.26 | 0 | miRTarBase | -0.1 | 3.0E-5 | 23169640 | We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation; Interestingly we found that miR-155 directly targets HDAC4 a corepressor partner of BCL6; Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4; Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias |
118 | hsa-miR-375 | BEND6 | 2.1 | 0 | 0.6 | 2.0E-5 | miRanda | -0.13 | 0 | NA | |
119 | hsa-miR-28-5p | BHLHE40 | -0.14 | 0.04976 | 0.41 | 0.00047 | miRanda | -0.47 | 0 | NA | |
120 | hsa-miR-15a-5p | BMI1 | 0.81 | 0 | 0.32 | 0.00051 | miRTarBase | -0.11 | 0.00226 | 27596816 | Our results suggest that overexpression of miR-15a and miR-16 mediates down-regulation of BMI1 and leads to mitochondrial mediated apoptosis |
121 | hsa-miR-21-5p | BMPR2 | 2.32 | 0 | -0.62 | 0 | miRTarBase | -0.22 | 0 | NA | |
122 | hsa-miR-155-5p | BRPF3 | 1.1 | 0 | 0.09 | 0.20587 | miRTarBase | -0.1 | 0 | NA | |
123 | hsa-miR-21-5p | BTG2 | 2.32 | 0 | -0.81 | 0 | miRTarBase | -0.27 | 0 | 24821435 | miR 21 regulates N methyl N nitro N' nitrosoguanidine induced gastric tumorigenesis by targeting FASLG and BTG2 |
124 | hsa-miR-28-5p | BTRC | -0.14 | 0.04976 | 0.12 | 0.15929 | miRanda | -0.25 | 0 | NA | |
125 | hsa-miR-193a-3p | C7 | 0.31 | 0.00478 | -3.46 | 0 | miRanda | -0.72 | 0 | NA | |
126 | hsa-miR-330-5p | C7 | 0.63 | 0 | -3.46 | 0 | miRanda | -0.79 | 0 | NA | |
127 | hsa-miR-375 | C7 | 2.1 | 0 | -3.46 | 0 | miRanda | -0.16 | 0.00108 | NA | |
128 | hsa-miR-590-3p | C7 | 1.27 | 0 | -3.46 | 0 | miRanda | -0.79 | 0 | NA | |
129 | hsa-miR-590-5p | C7 | 0.75 | 0 | -3.46 | 0 | miRanda | -0.87 | 0 | NA | |
130 | hsa-miR-361-5p | CAB39L | -0.1 | 0.09543 | -1.42 | 0 | miRanda | -0.33 | 0 | NA | |
131 | hsa-miR-542-3p | CAB39L | 0.57 | 0 | -1.42 | 0 | miRanda | -0.12 | 0.00057 | NA | |
132 | hsa-miR-590-3p | CAB39L | 1.27 | 0 | -1.42 | 0 | miRanda | -0.29 | 0 | NA | |
133 | hsa-miR-590-5p | CAB39L | 0.75 | 0 | -1.42 | 0 | miRanda | -0.27 | 0 | NA | |
134 | hsa-miR-28-5p | CACNG4 | -0.14 | 0.04976 | 2.21 | 0 | miRanda | -0.63 | 2.0E-5 | NA | |
135 | hsa-miR-15a-5p | CADM1 | 0.81 | 0 | -0.07 | 0.58588 | miRTarBase | -0.2 | 4.0E-5 | NA | |
136 | hsa-miR-28-5p | CALCOCO1 | -0.14 | 0.04976 | -1.08 | 0 | miRanda | -0.14 | 8.0E-5 | NA | |
137 | hsa-miR-28-5p | CALCOCO2 | -0.14 | 0.04976 | -0.44 | 0 | miRanda | -0.2 | 0 | NA | |
138 | hsa-miR-28-5p | CANT1 | -0.14 | 0.04976 | 1.19 | 0 | miRanda | -0.31 | 0 | NA | |
139 | hsa-miR-324-5p | CAPN6 | 0.21 | 0.13941 | -3.62 | 0 | miRanda | -0.18 | 0.03887 | NA | |
140 | hsa-miR-330-5p | CAPN6 | 0.63 | 0 | -3.62 | 0 | miRanda | -0.31 | 0.007 | NA | |
141 | hsa-miR-429 | CAPN6 | 2.84 | 0 | -3.62 | 0 | miRanda | -0.42 | 0 | NA | |
142 | hsa-miR-28-5p | CASC2 | -0.14 | 0.04976 | -0.06 | 0.56145 | miRanda | -0.21 | 1.0E-5 | NA | |
143 | hsa-miR-103a-3p | CAV1 | 0.61 | 0 | -3.35 | 0 | miRTarBase | -0.52 | 0 | NA | |
144 | hsa-miR-142-3p | CAV1 | 1.54 | 0 | -3.35 | 0 | miRanda | -0.24 | 0 | NA | |
145 | hsa-miR-320b | CAV1 | 0.41 | 0.00113 | -3.35 | 0 | miRanda | -0.21 | 0 | NA | |
146 | hsa-miR-342-3p | CAV1 | 1.22 | 0 | -3.35 | 0 | miRanda | -0.37 | 0 | NA | |
147 | hsa-miR-28-5p | CCDC113 | -0.14 | 0.04976 | 0.15 | 0.13693 | miRanda | -0.15 | 0.0019 | NA | |
148 | hsa-miR-28-5p | CCDC114 | -0.14 | 0.04976 | 1.17 | 0 | miRanda | -0.3 | 0.00046 | NA | |
149 | hsa-miR-375 | CCDC129 | 2.1 | 0 | -2.66 | 0 | miRanda | -0.28 | 0 | NA | |
150 | hsa-miR-375 | CCDC80 | 2.1 | 0 | -1.64 | 0 | miRanda | -0.16 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | RESPONSE TO ENDOGENOUS STIMULUS | 115 | 1450 | 1.013e-13 | 3.016e-10 |
2 | REGULATION OF CELL DIFFERENTIATION | 117 | 1492 | 1.296e-13 | 3.016e-10 |
3 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 94 | 1142 | 3.097e-12 | 4.804e-09 |
4 | REGULATION OF CELL PROLIFERATION | 111 | 1496 | 2.017e-11 | 2.347e-08 |
5 | RESPONSE TO HORMONE | 77 | 893 | 3.861e-11 | 3.593e-08 |
6 | MUSCLE STRUCTURE DEVELOPMENT | 48 | 432 | 5.885e-11 | 4.564e-08 |
7 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 118 | 1672 | 1.026e-10 | 6.818e-08 |
8 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 77 | 917 | 1.358e-10 | 7.899e-08 |
9 | NEUROGENESIS | 103 | 1402 | 2.094e-10 | 9.373e-08 |
10 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 69 | 788 | 2.216e-10 | 9.373e-08 |
11 | CIRCULATORY SYSTEM DEVELOPMENT | 69 | 788 | 2.216e-10 | 9.373e-08 |
12 | RESPONSE TO LIPID | 74 | 888 | 4.5e-10 | 1.745e-07 |
13 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 100 | 1381 | 8.727e-10 | 3.123e-07 |
14 | TISSUE DEVELOPMENT | 107 | 1518 | 9.462e-10 | 3.145e-07 |
15 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 61 | 689 | 1.706e-09 | 5.292e-07 |
16 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 79 | 1008 | 1.933e-09 | 5.622e-07 |
17 | RESPONSE TO ESTRADIOL | 24 | 146 | 2.074e-09 | 5.677e-07 |
18 | RESPONSE TO STEROID HORMONE | 49 | 497 | 2.275e-09 | 5.882e-07 |
19 | RESPONSE TO ALCOHOL | 40 | 362 | 2.816e-09 | 6.553e-07 |
20 | REGULATION OF CELL DEVELOPMENT | 69 | 836 | 2.709e-09 | 6.553e-07 |
21 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 68 | 823 | 3.405e-09 | 7.544e-07 |
22 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 121 | 1848 | 5.589e-09 | 1.182e-06 |
23 | RESPONSE TO ESTROGEN | 29 | 218 | 7.152e-09 | 1.447e-06 |
24 | RESPONSE TO NITROGEN COMPOUND | 69 | 859 | 8.213e-09 | 1.585e-06 |
25 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 19 | 100 | 8.515e-09 | 1.585e-06 |
26 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 69 | 872 | 1.5e-08 | 2.685e-06 |
27 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 62 | 750 | 1.705e-08 | 2.886e-06 |
28 | RESPONSE TO OXYGEN LEVELS | 35 | 311 | 1.737e-08 | 2.886e-06 |
29 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 63 | 771 | 2.011e-08 | 3.226e-06 |
30 | VASCULATURE DEVELOPMENT | 45 | 469 | 2.365e-08 | 3.668e-06 |
31 | RESPONSE TO ACID CHEMICAL | 35 | 319 | 3.314e-08 | 4.974e-06 |
32 | NEGATIVE REGULATION OF CELL PROLIFERATION | 55 | 643 | 3.618e-08 | 5.26e-06 |
33 | ORGAN GROWTH | 15 | 68 | 3.876e-08 | 5.465e-06 |
34 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 106 | 1618 | 5.617e-08 | 7.687e-06 |
35 | REGULATION OF LIPID METABOLIC PROCESS | 32 | 282 | 5.85e-08 | 7.778e-06 |
36 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 32 | 285 | 7.498e-08 | 9.692e-06 |
37 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 21 | 138 | 8.355e-08 | 1.051e-05 |
38 | ORGAN MORPHOGENESIS | 65 | 841 | 9.62e-08 | 1.129e-05 |
39 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 94 | 1395 | 9.702e-08 | 1.129e-05 |
40 | GLAND DEVELOPMENT | 39 | 395 | 9.689e-08 | 1.129e-05 |
41 | MUSCLE ORGAN DEVELOPMENT | 31 | 277 | 1.289e-07 | 1.463e-05 |
42 | POSITIVE REGULATION OF CELL PROLIFERATION | 63 | 814 | 1.456e-07 | 1.55e-05 |
43 | AGING | 30 | 264 | 1.467e-07 | 1.55e-05 |
44 | PROTEIN PHOSPHORYLATION | 70 | 944 | 1.499e-07 | 1.55e-05 |
45 | HEART DEVELOPMENT | 43 | 466 | 1.467e-07 | 1.55e-05 |
46 | TUBE DEVELOPMENT | 48 | 552 | 1.676e-07 | 1.666e-05 |
47 | HEAD DEVELOPMENT | 57 | 709 | 1.683e-07 | 1.666e-05 |
48 | RESPONSE TO GROWTH FACTOR | 43 | 475 | 2.491e-07 | 2.415e-05 |
49 | REGULATION OF NEURON DIFFERENTIATION | 47 | 554 | 4.609e-07 | 4.377e-05 |
50 | CELL DEVELOPMENT | 93 | 1426 | 4.968e-07 | 4.623e-05 |
51 | FOREBRAIN DEVELOPMENT | 35 | 357 | 5.197e-07 | 4.742e-05 |
52 | REGULATION OF CELL DEATH | 95 | 1472 | 5.89e-07 | 5.271e-05 |
53 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 72 | 1021 | 6.685e-07 | 5.869e-05 |
54 | NEGATIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 10 | 36 | 7.416e-07 | 6.39e-05 |
55 | DEVELOPMENTAL GROWTH | 33 | 333 | 8.613e-07 | 7.287e-05 |
56 | RESPONSE TO ABIOTIC STIMULUS | 71 | 1024 | 1.482e-06 | 0.0001232 |
57 | RESPONSE TO EXTERNAL STIMULUS | 110 | 1821 | 1.745e-06 | 0.0001425 |
58 | UROGENITAL SYSTEM DEVELOPMENT | 30 | 299 | 2.088e-06 | 0.0001675 |
59 | BLOOD VESSEL MORPHOGENESIS | 34 | 364 | 2.254e-06 | 0.0001778 |
60 | CELLULAR RESPONSE TO HORMONE STIMULUS | 45 | 552 | 2.378e-06 | 0.0001821 |
61 | RESPONSE TO KETONE | 22 | 182 | 2.388e-06 | 0.0001821 |
62 | HEMIDESMOSOME ASSEMBLY | 6 | 12 | 2.531e-06 | 0.0001899 |
63 | REGULATION OF PROTEIN MODIFICATION PROCESS | 104 | 1710 | 2.574e-06 | 0.0001901 |
64 | SINGLE ORGANISM BEHAVIOR | 35 | 384 | 2.796e-06 | 0.0002033 |
65 | EXTRACELLULAR STRUCTURE ORGANIZATION | 30 | 304 | 2.932e-06 | 0.0002099 |
66 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 19 | 144 | 3.143e-06 | 0.0002206 |
67 | NEGATIVE REGULATION OF CELL DEATH | 62 | 872 | 3.177e-06 | 0.0002206 |
68 | MUSCLE TISSUE DEVELOPMENT | 28 | 275 | 3.418e-06 | 0.0002272 |
69 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 108 | 1805 | 3.401e-06 | 0.0002272 |
70 | RESPONSE TO PURINE CONTAINING COMPOUND | 20 | 158 | 3.34e-06 | 0.0002272 |
71 | REGULATION OF GROWTH | 49 | 633 | 3.652e-06 | 0.0002393 |
72 | POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 12 | 62 | 3.877e-06 | 0.0002505 |
73 | RESPONSE TO EXTRACELLULAR STIMULUS | 38 | 441 | 4.044e-06 | 0.0002578 |
74 | GLAND MORPHOGENESIS | 15 | 97 | 4.752e-06 | 0.0002909 |
75 | POSITIVE REGULATION OF GENE EXPRESSION | 104 | 1733 | 4.652e-06 | 0.0002909 |
76 | DIGESTIVE SYSTEM DEVELOPMENT | 19 | 148 | 4.737e-06 | 0.0002909 |
77 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 41 | 498 | 5.247e-06 | 0.0003165 |
78 | RESPONSE TO NUTRIENT | 22 | 191 | 5.305e-06 | 0.0003165 |
79 | EPITHELIUM DEVELOPMENT | 65 | 945 | 5.455e-06 | 0.0003213 |
80 | COGNITION | 26 | 251 | 5.549e-06 | 0.0003227 |
81 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 93 | 1518 | 6.927e-06 | 0.0003864 |
82 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 106 | 1791 | 6.87e-06 | 0.0003864 |
83 | CONNECTIVE TISSUE DEVELOPMENT | 22 | 194 | 6.837e-06 | 0.0003864 |
84 | POSITIVE REGULATION OF GLUCOSE METABOLIC PROCESS | 9 | 36 | 6.976e-06 | 0.0003864 |
85 | NEGATIVE REGULATION OF CELL COMMUNICATION | 77 | 1192 | 7.316e-06 | 0.0004005 |
86 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 6 | 14 | 7.693e-06 | 0.0004162 |
87 | POSITIVE REGULATION OF LOCOMOTION | 36 | 420 | 8.122e-06 | 0.0004344 |
88 | RESPONSE TO PEPTIDE | 35 | 404 | 8.592e-06 | 0.0004543 |
89 | RESPONSE TO WOUNDING | 44 | 563 | 9.025e-06 | 0.0004718 |
90 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 99 | 1656 | 9.507e-06 | 0.0004909 |
91 | TELENCEPHALON DEVELOPMENT | 24 | 228 | 9.609e-06 | 0.0004909 |
92 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 105 | 1784 | 9.706e-06 | 0.0004909 |
93 | RESPONSE TO CYTOKINE | 52 | 714 | 1.043e-05 | 0.0005216 |
94 | REGULATION OF HYDROLASE ACTIVITY | 83 | 1327 | 1.061e-05 | 0.0005253 |
95 | RESPONSE TO INORGANIC SUBSTANCE | 39 | 479 | 1.148e-05 | 0.0005623 |
96 | PHOSPHORYLATION | 78 | 1228 | 1.162e-05 | 0.0005632 |
97 | GROWTH | 35 | 410 | 1.181e-05 | 0.0005665 |
98 | LEARNING | 17 | 131 | 1.283e-05 | 0.0006092 |
99 | BIOLOGICAL ADHESION | 68 | 1032 | 1.364e-05 | 0.0006413 |
100 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 80 | 1275 | 1.384e-05 | 0.0006442 |
101 | RESPONSE TO DRUG | 36 | 431 | 1.431e-05 | 0.0006594 |
102 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 56 | 799 | 1.455e-05 | 0.0006636 |
103 | SECOND MESSENGER MEDIATED SIGNALING | 19 | 160 | 1.481e-05 | 0.0006692 |
104 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 68 | 1036 | 1.545e-05 | 0.0006794 |
105 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 68 | 1036 | 1.545e-05 | 0.0006794 |
106 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 56 | 801 | 1.562e-05 | 0.0006794 |
107 | RHYTHMIC PROCESS | 28 | 298 | 1.561e-05 | 0.0006794 |
108 | REGULATION OF GLUCOSE IMPORT | 11 | 60 | 1.685e-05 | 0.000726 |
109 | MAMMARY GLAND MORPHOGENESIS | 9 | 40 | 1.763e-05 | 0.000739 |
110 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 9 | 40 | 1.763e-05 | 0.000739 |
111 | RESPONSE TO FATTY ACID | 13 | 83 | 1.758e-05 | 0.000739 |
112 | CELL SUBSTRATE JUNCTION ASSEMBLY | 9 | 41 | 2.182e-05 | 0.0009063 |
113 | REGULATION OF ORGAN GROWTH | 12 | 73 | 2.233e-05 | 0.0009193 |
114 | RESPONSE TO MECHANICAL STIMULUS | 22 | 210 | 2.406e-05 | 0.000982 |
115 | HOMEOSTATIC PROCESS | 82 | 1337 | 2.437e-05 | 0.0009861 |
116 | CHEMICAL HOMEOSTASIS | 59 | 874 | 2.585e-05 | 0.001034 |
117 | SECRETION | 44 | 588 | 2.619e-05 | 0.001034 |
118 | LOCOMOTION | 71 | 1114 | 2.623e-05 | 0.001034 |
119 | INTRACELLULAR SIGNAL TRANSDUCTION | 93 | 1572 | 2.725e-05 | 0.001057 |
120 | CELL FATE COMMITMENT | 23 | 227 | 2.708e-05 | 0.001057 |
121 | VESICLE MEDIATED TRANSPORT | 77 | 1239 | 2.809e-05 | 0.00108 |
122 | ARTERY DEVELOPMENT | 12 | 75 | 2.955e-05 | 0.001127 |
123 | POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 10 | 53 | 3.132e-05 | 0.001185 |
124 | REGULATION OF PHOSPHOLIPASE ACTIVITY | 11 | 64 | 3.175e-05 | 0.001192 |
125 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 26 | 278 | 3.366e-05 | 0.001243 |
126 | REGULATION OF STEM CELL PROLIFERATION | 13 | 88 | 3.34e-05 | 0.001243 |
127 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 109 | 1929 | 3.708e-05 | 0.001303 |
128 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 60 | 905 | 3.723e-05 | 0.001303 |
129 | REGULATION OF MESENCHYMAL CELL PROLIFERATION | 8 | 34 | 3.667e-05 | 0.001303 |
130 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 41 | 541 | 3.687e-05 | 0.001303 |
131 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 16 | 128 | 3.662e-05 | 0.001303 |
132 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 65 | 1004 | 3.638e-05 | 0.001303 |
133 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 41 | 541 | 3.687e-05 | 0.001303 |
134 | REGULATION OF SYSTEM PROCESS | 39 | 507 | 4.108e-05 | 0.001426 |
135 | POSITIVE REGULATION OF CELL DEVELOPMENT | 37 | 472 | 4.328e-05 | 0.001492 |
136 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 82 | 1360 | 4.423e-05 | 0.001513 |
137 | SKELETAL SYSTEM DEVELOPMENT | 36 | 455 | 4.518e-05 | 0.001534 |
138 | MAMMARY GLAND DEVELOPMENT | 15 | 117 | 4.728e-05 | 0.001594 |
139 | REGULATION OF KINASE ACTIVITY | 53 | 776 | 4.918e-05 | 0.001646 |
140 | CELLULAR RESPONSE TO ACID CHEMICAL | 19 | 175 | 5.212e-05 | 0.001708 |
141 | POSITIVE REGULATION OF CELL DEATH | 44 | 605 | 5.145e-05 | 0.001708 |
142 | MESENCHYME DEVELOPMENT | 20 | 190 | 5.2e-05 | 0.001708 |
143 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 62 | 957 | 5.413e-05 | 0.001761 |
144 | REGENERATION | 18 | 161 | 5.542e-05 | 0.001791 |
145 | RESPONSE TO CORTICOSTEROID | 19 | 176 | 5.635e-05 | 0.001808 |
146 | CARTILAGE DEVELOPMENT | 17 | 147 | 5.776e-05 | 0.001841 |
147 | FIBRIL ORGANIZATION | 6 | 19 | 5.884e-05 | 0.001862 |
148 | REGULATION OF GLUCOSE METABOLIC PROCESS | 14 | 106 | 6.03e-05 | 0.001883 |
149 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 44 | 609 | 5.998e-05 | 0.001883 |
150 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 63 | 983 | 6.445e-05 | 0.001999 |
151 | LIPID MODIFICATION | 21 | 210 | 7.229e-05 | 0.002228 |
152 | REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 7 | 28 | 7.47e-05 | 0.002236 |
153 | MUSCLE HYPERTROPHY | 7 | 28 | 7.47e-05 | 0.002236 |
154 | REGULATION OF FATTY ACID OXIDATION | 7 | 28 | 7.47e-05 | 0.002236 |
155 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 11 | 70 | 7.48e-05 | 0.002236 |
156 | REGULATION OF MUSCLE SYSTEM PROCESS | 20 | 195 | 7.496e-05 | 0.002236 |
157 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 71 | 1152 | 7.555e-05 | 0.002239 |
158 | SECRETION BY CELL | 37 | 486 | 7.962e-05 | 0.002345 |
159 | MELANOCYTE DIFFERENTIATION | 6 | 20 | 8.131e-05 | 0.002379 |
160 | REGULATION OF LIPID KINASE ACTIVITY | 9 | 48 | 8.191e-05 | 0.002382 |
161 | HEART MORPHOGENESIS | 21 | 212 | 8.286e-05 | 0.002395 |
162 | LIPOPROTEIN TRANSPORT | 5 | 13 | 8.615e-05 | 0.002444 |
163 | LIPOPROTEIN LOCALIZATION | 5 | 13 | 8.615e-05 | 0.002444 |
164 | REGULATION OF CHOLESTEROL STORAGE | 5 | 13 | 8.615e-05 | 0.002444 |
165 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 22 | 229 | 8.934e-05 | 0.002519 |
166 | NEURON DIFFERENTIATION | 57 | 874 | 9.082e-05 | 0.002546 |
167 | CELL MOTILITY | 55 | 835 | 9.317e-05 | 0.002581 |
168 | LOCALIZATION OF CELL | 55 | 835 | 9.317e-05 | 0.002581 |
169 | REGULATION OF SMOOTH MUSCLE CONTRACTION | 10 | 60 | 9.48e-05 | 0.00261 |
170 | REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 9 | 49 | 9.693e-05 | 0.002637 |
171 | PATTERN SPECIFICATION PROCESS | 33 | 418 | 9.666e-05 | 0.002637 |
172 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 17 | 154 | 0.0001036 | 0.002802 |
173 | REGULATION OF PHOSPHOLIPASE C ACTIVITY | 8 | 39 | 0.0001047 | 0.002809 |
174 | REGULATION OF TRANSPORT | 101 | 1804 | 0.0001051 | 0.002809 |
175 | CELLULAR COMPONENT MORPHOGENESIS | 58 | 900 | 0.0001087 | 0.002889 |
176 | CELLULAR RESPONSE TO LIPID | 35 | 457 | 0.0001096 | 0.002899 |
177 | RESPONSE TO METAL ION | 28 | 333 | 0.0001119 | 0.002941 |
178 | NEGATIVE REGULATION OF CELL MATRIX ADHESION | 7 | 30 | 0.00012 | 0.00312 |
179 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 7 | 30 | 0.00012 | 0.00312 |
180 | REGULATION OF FATTY ACID METABOLIC PROCESS | 12 | 87 | 0.0001312 | 0.003392 |
181 | ARTERY MORPHOGENESIS | 9 | 51 | 0.0001339 | 0.003443 |
182 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 32 | 408 | 0.0001384 | 0.003538 |
183 | REGULATION OF CELL SUBSTRATE ADHESION | 18 | 173 | 0.0001407 | 0.003578 |
184 | REGULATION OF LIPID STORAGE | 8 | 41 | 0.0001518 | 0.003839 |
185 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 35 | 465 | 0.0001536 | 0.003863 |
186 | NEGATIVE REGULATION OF ERK1 AND ERK2 CASCADE | 9 | 52 | 0.0001565 | 0.003866 |
187 | REGULATION OF ERK1 AND ERK2 CASCADE | 22 | 238 | 0.0001567 | 0.003866 |
188 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 108 | 1977 | 0.000155 | 0.003866 |
189 | STEM CELL DIFFERENTIATION | 19 | 190 | 0.000157 | 0.003866 |
190 | GLIOGENESIS | 18 | 175 | 0.0001628 | 0.003986 |
191 | REGULATION OF DEVELOPMENTAL GROWTH | 25 | 289 | 0.0001652 | 0.004024 |
192 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 37 | 505 | 0.0001728 | 0.004187 |
193 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 9 | 53 | 0.000182 | 0.004322 |
194 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 9 | 53 | 0.000182 | 0.004322 |
195 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 8 | 42 | 0.0001812 | 0.004322 |
196 | REGULATION OF HEART GROWTH | 8 | 42 | 0.0001812 | 0.004322 |
197 | NEURON PROJECTION DEVELOPMENT | 39 | 545 | 0.0001893 | 0.004448 |
198 | EYE DEVELOPMENT | 27 | 326 | 0.0001886 | 0.004448 |
199 | RESPONSE TO CAMP | 13 | 104 | 0.0001927 | 0.004484 |
200 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 13 | 104 | 0.0001927 | 0.004484 |
201 | EXOCYTOSIS | 26 | 310 | 0.0002021 | 0.004677 |
202 | CELL MATRIX ADHESION | 14 | 119 | 0.0002122 | 0.004887 |
203 | REGULATION OF VASOCONSTRICTION | 10 | 66 | 0.0002152 | 0.004908 |
204 | POSITIVE REGULATION OF LIPASE ACTIVITY | 10 | 66 | 0.0002152 | 0.004908 |
205 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 85 | 1492 | 0.0002205 | 0.005005 |
206 | MESENCHYMAL CELL DIFFERENTIATION | 15 | 134 | 0.0002228 | 0.005032 |
207 | POSITIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 7 | 33 | 0.0002276 | 0.005116 |
208 | REGULATION OF FAT CELL DIFFERENTIATION | 13 | 106 | 0.0002335 | 0.005224 |
209 | TISSUE MORPHOGENESIS | 38 | 533 | 0.0002452 | 0.005434 |
210 | REGULATION OF CELL ADHESION | 43 | 629 | 0.0002452 | 0.005434 |
211 | MULTI MULTICELLULAR ORGANISM PROCESS | 20 | 213 | 0.0002494 | 0.0055 |
212 | RESPIRATORY SYSTEM DEVELOPMENT | 19 | 197 | 0.0002509 | 0.005508 |
213 | NEGATIVE REGULATION OF PHOSPHORYLATION | 32 | 422 | 0.0002544 | 0.005558 |
214 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 17 | 166 | 0.000258 | 0.00561 |
215 | EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 14 | 122 | 0.0002758 | 0.005968 |
216 | MUSCLE SYSTEM PROCESS | 24 | 282 | 0.0002821 | 0.005995 |
217 | POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 9 | 56 | 0.0002806 | 0.005995 |
218 | OUTFLOW TRACT MORPHOGENESIS | 9 | 56 | 0.0002806 | 0.005995 |
219 | RESPONSE TO OXIDATIVE STRESS | 28 | 352 | 0.0002819 | 0.005995 |
220 | REGULATION OF FIBROBLAST PROLIFERATION | 11 | 81 | 0.0002848 | 0.006024 |
221 | REGULATION OF GTPASE ACTIVITY | 45 | 673 | 0.0002886 | 0.006076 |
222 | REGULATION OF CELL PROJECTION ORGANIZATION | 39 | 558 | 0.0003042 | 0.006355 |
223 | PALLIUM DEVELOPMENT | 16 | 153 | 0.0003059 | 0.006355 |
224 | EMBRYONIC MORPHOGENESIS | 38 | 539 | 0.0003057 | 0.006355 |
225 | REGULATION OF VASCULATURE DEVELOPMENT | 21 | 233 | 0.0003093 | 0.006397 |
226 | POSITIVE REGULATION OF CELL COMMUNICATION | 86 | 1532 | 0.0003263 | 0.006719 |
227 | RESPONSE TO ORGANOPHOSPHORUS | 15 | 139 | 0.0003328 | 0.006791 |
228 | OSSIFICATION | 22 | 251 | 0.0003322 | 0.006791 |
229 | RESPONSE TO MINERALOCORTICOID | 7 | 35 | 0.0003349 | 0.006805 |
230 | CYCLIC NUCLEOTIDE MEDIATED SIGNALING | 8 | 46 | 0.0003494 | 0.007069 |
231 | REGULATION OF LIPASE ACTIVITY | 11 | 83 | 0.0003535 | 0.00709 |
232 | LIPID OXIDATION | 10 | 70 | 0.000352 | 0.00709 |
233 | BRANCH ELONGATION OF AN EPITHELIUM | 5 | 17 | 0.0003639 | 0.007133 |
234 | POSITIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 5 | 17 | 0.0003639 | 0.007133 |
235 | NEGATIVE REGULATION OF ANOIKIS | 5 | 17 | 0.0003639 | 0.007133 |
236 | CELL PROJECTION ORGANIZATION | 56 | 902 | 0.0003647 | 0.007133 |
237 | DEFINITIVE HEMOPOIESIS | 5 | 17 | 0.0003639 | 0.007133 |
238 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 48 | 740 | 0.0003648 | 0.007133 |
239 | NEGATIVE REGULATION OF GROWTH | 21 | 236 | 0.0003675 | 0.007154 |
240 | EPIDERMIS DEVELOPMENT | 22 | 253 | 0.0003707 | 0.007188 |
241 | BONE DEVELOPMENT | 16 | 156 | 0.000381 | 0.007356 |
242 | MUSCLE CELL DIFFERENTIATION | 21 | 237 | 0.0003889 | 0.007477 |
243 | REGULATION OF TRANSFERASE ACTIVITY | 58 | 946 | 0.0003938 | 0.007541 |
244 | RESPONSE TO CORTICOSTERONE | 6 | 26 | 0.0003958 | 0.007548 |
245 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 13 | 112 | 0.0004031 | 0.007656 |
246 | MEMORY | 12 | 98 | 0.0004076 | 0.00771 |
247 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 23 | 272 | 0.0004105 | 0.007711 |
248 | ENDOCYTOSIS | 36 | 509 | 0.000411 | 0.007711 |
249 | REGULATION OF ANATOMICAL STRUCTURE SIZE | 34 | 472 | 0.0004249 | 0.007941 |
250 | REGULATION OF STEM CELL DIFFERENTIATION | 13 | 113 | 0.0004397 | 0.008183 |
251 | NEURON DEVELOPMENT | 45 | 687 | 0.0004491 | 0.008293 |
252 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 18 | 190 | 0.0004486 | 0.008293 |
253 | SENSORY ORGAN DEVELOPMENT | 35 | 493 | 0.0004593 | 0.008446 |
254 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 32 | 437 | 0.0004686 | 0.008583 |
255 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 9 | 60 | 0.0004769 | 0.008685 |
256 | RESPONSE TO REACTIVE OXYGEN SPECIES | 18 | 191 | 0.0004778 | 0.008685 |
257 | REGULATED EXOCYTOSIS | 20 | 224 | 0.0004807 | 0.008703 |
258 | CARDIAC CHAMBER DEVELOPMENT | 15 | 144 | 0.0004865 | 0.008765 |
259 | RESPONSE TO CAFFEINE | 5 | 18 | 0.0004879 | 0.008765 |
260 | POSITIVE REGULATION OF HEART GROWTH | 6 | 27 | 0.0004923 | 0.008811 |
261 | EMBRYO DEVELOPMENT | 55 | 894 | 0.0005109 | 0.009108 |
262 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 13 | 115 | 0.0005213 | 0.009258 |
263 | BEHAVIOR | 36 | 516 | 0.000529 | 0.009359 |
264 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 9 | 61 | 0.0005405 | 0.009526 |
265 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 30 | 404 | 0.0005542 | 0.009731 |
266 | COLLAGEN FIBRIL ORGANIZATION | 7 | 38 | 0.0005682 | 0.009828 |
267 | OXIDATION REDUCTION PROCESS | 55 | 898 | 0.0005679 | 0.009828 |
268 | REGULATION OF RENAL SYSTEM PROCESS | 7 | 38 | 0.0005682 | 0.009828 |
269 | POSITIVE REGULATION OF ORGAN GROWTH | 7 | 38 | 0.0005682 | 0.009828 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | GROWTH FACTOR BINDING | 20 | 123 | 5.476e-08 | 5.087e-05 |
2 | GLYCOSAMINOGLYCAN BINDING | 26 | 205 | 1.133e-07 | 5.262e-05 |
3 | SULFUR COMPOUND BINDING | 27 | 234 | 4.509e-07 | 0.0001396 |
4 | PROTEIN KINASE ACTIVITY | 51 | 640 | 9.918e-07 | 0.0002304 |
5 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 50 | 629 | 1.362e-06 | 0.0002531 |
6 | HEPARIN BINDING | 20 | 157 | 3.026e-06 | 0.0004685 |
7 | KINASE ACTIVITY | 59 | 842 | 8.615e-06 | 0.001143 |
8 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 30 | 328 | 1.327e-05 | 0.001541 |
9 | MACROMOLECULAR COMPLEX BINDING | 85 | 1399 | 2.413e-05 | 0.002491 |
10 | DOUBLE STRANDED DNA BINDING | 53 | 764 | 3.255e-05 | 0.002955 |
11 | CORE PROMOTER SEQUENCE SPECIFIC DNA BINDING | 14 | 101 | 3.498e-05 | 0.002955 |
12 | REGULATORY REGION NUCLEIC ACID BINDING | 55 | 818 | 5.413e-05 | 0.003868 |
13 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 74 | 1199 | 5.07e-05 | 0.003868 |
14 | TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY | 12 | 81 | 6.468e-05 | 0.004292 |
15 | ENZYME BINDING | 98 | 1737 | 0.0001013 | 0.005722 |
16 | PROTEIN DOMAIN SPECIFIC BINDING | 44 | 624 | 0.0001047 | 0.005722 |
17 | SEQUENCE SPECIFIC DNA BINDING | 65 | 1037 | 9.446e-05 | 0.005722 |
18 | FLAVIN ADENINE DINUCLEOTIDE BINDING | 11 | 74 | 0.0001255 | 0.006357 |
19 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 30 | 371 | 0.00013 | 0.006357 |
20 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 34 | 445 | 0.0001432 | 0.00665 |
21 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II DISTAL ENHANCER SEQUENCE SPECIFIC BINDING | 12 | 90 | 0.0001822 | 0.008062 |
22 | KINASE BINDING | 42 | 606 | 0.0002162 | 0.009131 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | EXTRACELLULAR MATRIX | 46 | 426 | 3.848e-10 | 2.247e-07 |
2 | MEMBRANE REGION | 87 | 1134 | 7.789e-10 | 2.274e-07 |
3 | PROTEINACEOUS EXTRACELLULAR MATRIX | 38 | 356 | 1.806e-08 | 3.516e-06 |
4 | EXTRACELLULAR MATRIX COMPONENT | 19 | 125 | 3.494e-07 | 5.101e-05 |
5 | GOLGI APPARATUS | 94 | 1445 | 4.793e-07 | 5.598e-05 |
6 | SYNAPSE | 56 | 754 | 2.636e-06 | 0.0002566 |
7 | PLASMA MEMBRANE REGION | 65 | 929 | 3.114e-06 | 0.0002598 |
8 | BASEMENT MEMBRANE | 14 | 93 | 1.347e-05 | 0.0009831 |
9 | MEMBRANE MICRODOMAIN | 27 | 288 | 2.293e-05 | 0.001488 |
10 | EXTRACELLULAR SPACE | 83 | 1376 | 3.904e-05 | 0.00228 |
11 | COATED PIT | 11 | 67 | 4.937e-05 | 0.002403 |
12 | GOLGI APPARATUS PART | 59 | 893 | 4.766e-05 | 0.002403 |
13 | SYNAPSE PART | 44 | 610 | 6.231e-05 | 0.002799 |
14 | EXCITATORY SYNAPSE | 20 | 197 | 8.642e-05 | 0.003365 |
15 | INTRACELLULAR VESICLE | 76 | 1259 | 8.214e-05 | 0.003365 |
16 | NEURONAL POSTSYNAPTIC DENSITY | 9 | 53 | 0.000182 | 0.006585 |
17 | CLATHRIN VESICLE COAT | 6 | 23 | 0.0001917 | 0.006585 |
18 | VESICLE COAT | 8 | 45 | 0.0002987 | 0.00969 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Focal_adhesion_hsa04510 | 29 | 199 | 8.403e-10 | 4.37e-08 | |
2 | AMPK_signaling_pathway_hsa04152 | 21 | 121 | 7.742e-09 | 2.013e-07 | |
3 | PI3K_Akt_signaling_pathway_hsa04151 | 38 | 352 | 1.33e-08 | 2.305e-07 | |
4 | MAPK_signaling_pathway_hsa04010 | 31 | 295 | 5.226e-07 | 6.794e-06 | |
5 | FoxO_signaling_pathway_hsa04068 | 18 | 132 | 3.534e-06 | 3.675e-05 | |
6 | cAMP_signaling_pathway_hsa04024 | 21 | 198 | 3.045e-05 | 0.0002639 | |
7 | Rap1_signaling_pathway_hsa04015 | 21 | 206 | 5.467e-05 | 0.0003909 | |
8 | Jak_STAT_signaling_pathway_hsa04630 | 18 | 162 | 6.014e-05 | 0.0003909 | |
9 | Apelin_signaling_pathway_hsa04371 | 16 | 137 | 8.404e-05 | 0.0004855 | |
10 | ECM_receptor_interaction_hsa04512 | 11 | 82 | 0.0003176 | 0.001652 | |
11 | Hedgehog_signaling_pathway_hsa04340 | 8 | 47 | 0.0004069 | 0.001924 | |
12 | Phospholipase_D_signaling_pathway_hsa04072 | 15 | 146 | 0.0005632 | 0.002441 | |
13 | Ras_signaling_pathway_hsa04014 | 20 | 232 | 0.0007494 | 0.002998 | |
14 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 14 | 139 | 0.001033 | 0.003837 | |
15 | p53_signaling_pathway_hsa04115 | 9 | 68 | 0.001207 | 0.004185 | |
16 | Endocytosis_hsa04144 | 20 | 244 | 0.001391 | 0.004522 | |
17 | HIF_1_signaling_pathway_hsa04066 | 11 | 100 | 0.001713 | 0.005239 | |
18 | Cytokine_cytokine_receptor_interaction_hsa04060 | 21 | 270 | 0.002045 | 0.005909 | |
19 | TNF_signaling_pathway_hsa04668 | 11 | 108 | 0.003159 | 0.008231 | |
20 | Regulation_of_actin_cytoskeleton_hsa04810 | 17 | 208 | 0.003166 | 0.008231 | |
21 | Cellular_senescence_hsa04218 | 14 | 160 | 0.003863 | 0.009566 | |
22 | Calcium_signaling_pathway_hsa04020 | 15 | 182 | 0.00498 | 0.01177 | |
23 | ErbB_signaling_pathway_hsa04012 | 9 | 85 | 0.005639 | 0.01275 | |
24 | Hippo_signaling_pathway_hsa04390 | 13 | 154 | 0.007075 | 0.01533 | |
25 | Adherens_junction_hsa04520 | 7 | 72 | 0.02142 | 0.04455 | |
26 | Mitophagy_animal_hsa04137 | 6 | 65 | 0.03991 | 0.07983 | |
27 | Peroxisome_hsa04146 | 7 | 83 | 0.04215 | 0.08117 | |
28 | Neuroactive_ligand_receptor_interaction_hsa04080 | 17 | 278 | 0.04392 | 0.08156 | |
29 | cGMP_PKG_signaling_pathway_hsa04022 | 11 | 163 | 0.05311 | 0.09497 | |
30 | Gap_junction_hsa04540 | 7 | 88 | 0.05479 | 0.09497 | |
31 | Wnt_signaling_pathway_hsa04310 | 10 | 146 | 0.05832 | 0.09783 | |
32 | mTOR_signaling_pathway_hsa04150 | 10 | 151 | 0.06983 | 0.1135 | |
33 | Phosphatidylinositol_signaling_system_hsa04070 | 7 | 99 | 0.09017 | 0.1421 | |
34 | ABC_transporters_hsa02010 | 4 | 45 | 0.09608 | 0.1469 | |
35 | TGF_beta_signaling_pathway_hsa04350 | 6 | 84 | 0.1077 | 0.1601 | |
36 | Apoptosis_hsa04210 | 8 | 138 | 0.1683 | 0.2431 | |
37 | Sphingolipid_signaling_pathway_hsa04071 | 7 | 118 | 0.1748 | 0.2457 | |
38 | VEGF_signaling_pathway_hsa04370 | 4 | 59 | 0.1953 | 0.2673 | |
39 | Ferroptosis_hsa04216 | 3 | 40 | 0.2019 | 0.2689 | |
40 | Oocyte_meiosis_hsa04114 | 7 | 124 | 0.2069 | 0.2689 | |
41 | NF_kappa_B_signaling_pathway_hsa04064 | 5 | 95 | 0.3087 | 0.3851 | |
42 | Hippo_signaling_pathway_multiple_species_hsa04392 | 2 | 29 | 0.3111 | 0.3851 | |
43 | Cell_adhesion_molecules_.CAMs._hsa04514 | 7 | 145 | 0.3324 | 0.4016 | |
44 | Tight_junction_hsa04530 | 8 | 170 | 0.3398 | 0.4016 | |
45 | Autophagy_animal_hsa04140 | 6 | 128 | 0.378 | 0.4368 | |
46 | Lysosome_hsa04142 | 4 | 123 | 0.7078 | 0.7896 | |
47 | Cell_cycle_hsa04110 | 4 | 124 | 0.7137 | 0.7896 | |
48 | Necroptosis_hsa04217 | 3 | 164 | 0.956 | 0.9942 | |
49 | Phagosome_hsa04145 | 2 | 152 | 0.9829 | 1 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | MIR143HG |
hsa-miR-107;hsa-miR-193a-3p;hsa-miR-320b;hsa-miR-330-5p;hsa-miR-338-3p;hsa-miR-339-5p;hsa-miR-342-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 10 | SVEP1 | Sponge network | -4.451 | 0 | -3.504 | 0 | 0.756 |
2 | MIR143HG |
hsa-miR-193a-3p;hsa-miR-320b;hsa-miR-330-5p;hsa-miR-338-3p;hsa-miR-339-5p;hsa-miR-342-3p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PDGFRA | Sponge network | -4.451 | 0 | -1.842 | 0 | 0.597 |